News

ascopubs.org9d
Safety and Efficacy of Anti–Human Epidermal Growth Factor 2 Agents in the Treatment of Biliary Tract Cancers: A Systematic Review
Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials A comprehensive search of PubMed/MEDLINE and EMBASE was ...
ascopubs.org9d
Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials
The median time to recovery from G2/3 TRAE was determined as the date from start of G2/3 toxicity to date of recovery to immediate lower grade (G1/2, respectively) or resolution. Response to treatment ...
Pharmabiz1d
Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH
Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...
EurekAlert!10d
Screening history, stage at diagnosis, and mortality in screen-detected breast cancer
About The Study: In this cohort study of older women with screen-detected estrogen receptor–positive or human epidermal growth factor receptor 2–negative breast cancer, prior screening ...